Evidence map›Paper›PMID 42028305›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

Myval Octacor and Octapro T

Alfonso Ielasi, Rodolfo Caminiti, Mariano Pellicano, Andrea Marrone, Dario Pellegrini, Carlo Banfi, Mattia Glauber, Maurizio Tespili

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alfonso IelasiU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Rodolfo CaminitiU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Mariano PellicanoU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Andrea MarroneU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Dario PellegriniU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Carlo BanfiU.O. Cardiochirurgia Universitaria, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Mattia GlauberU.O. Cardiochirurgia Mini-Invasiva, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.
Maurizio TespiliU.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: the treatment of high-risk or inoperable patients with severe, pure native non calcified aortic regurgitation (NCAR) poses unique procedural challenges for the Methods: a retrospective cohort analysis was performed on consecutive high-risk surgical patients with severe, pure NCAR who underwent TAVI between January 2023 and June 2025 with the second (Octacor) and third (Octapro) generation of the Myval BE THV. Main end-points were technical and device success according to the Valve Academic Research Consortium (VARC) 3 criteria. The rates of permanent pace-maker implantation (PPI) and moderate-to-severe residual AR both, in-hospital and at the longest available follow-up were also evaluated. Results: during the study period, 32 patients (Octacor, n = 21 and Octapro, n = 11) with pure, NCAR were treated. Mean age was 79.3 ± 7.6 years while 81.2% were male. The mean left ventricular ejection fraction was 43.1 ± 7.4%. An XL size was implanted in 21 patients of whom 15 were 32 mm. The average percentage of THV oversize was 19.7 ± 6.9. Technical success was achieved in 87.5% of the cases due to partial migration of 4 THVs (all 32 mm implanted in large annuli) into the LVOT requiring rescue implantation of a second prosthesis. This strategy was effective in achieving a good result in 2 cases while in the remaining 2, the THVs embolized in the left ventricle requiring surgical conversion. No intraprocedural death or disabling strokes were reported. PPI rate at discharge was 9.4% while moderate residual AR was reported in 1 patient (including patient underwent successful rescue THV-in-THV). Device success was 87.5%. At 1-year follow-up, mortality and PPI rates were 3.1% and 15.6%, respectively with no severe residual AR cases reported. Conclusions: Octacor and Octapro BE THVs implantation in patients with pure NCAR is feasible and yields acceptable clinical outcomes in a high-risk population. Further studies are warranted to better understand the potential role of these THVs in this complex scenario.

Indexed as

Aortic regurgitationBalloon-expandable trans-catheter heart valveTranscatheter aortic valve implantation

Identifiers

PMID42028305
PMCPMC13099935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.